These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11727624)

  • 41. Prescription of rh-APC differs substantially among western European countries.
    Schultz MJ; Levi M
    Intensive Care Med; 2006 Apr; 32(4):630-1. PubMed ID: 16520998
    [No Abstract]   [Full Text] [Related]  

  • 42. Clinical expert round table discussion (session 3) at the Margaux Conference on Critical Illness: the role of activated protein C in severe sepsis.
    Bernard G; Artigas A; Dellinger P; Esmon C; Faist E; Faust SN; Fischer CJ; Fumagalli R; grinnell BW; Sprung C
    Crit Care Med; 2001 Jul; 29(7 Suppl):S75-7. PubMed ID: 11445738
    [No Abstract]   [Full Text] [Related]  

  • 43. Adventure of recombinant human activated protein C in sepsis and new treatment hopes on the horizon.
    Kaya S
    Recent Pat Inflamm Allergy Drug Discov; 2012 May; 6(2):159-64. PubMed ID: 22292553
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Simplified pharmacoeconomics of critical care and severe sepsis.
    Ernst FR; Levy H; Qualy RL
    J Intensive Care Med; 2007; 22(5):283-93. PubMed ID: 17895486
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Still puzzled by additional data from the PROWESS study.
    Schultz MJ
    Crit Care Med; 2005 Sep; 33(9):2146; author reply 2146-7. PubMed ID: 16148509
    [No Abstract]   [Full Text] [Related]  

  • 46. Circulating Histones in Sepsis: Potential Outcome Predictors and Therapeutic Targets.
    Li Y; Wan D; Luo X; Song T; Wang Y; Yu Q; Jiang L; Liao R; Zhao W; Su B
    Front Immunol; 2021; 12():650184. PubMed ID: 33868288
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Sepsis therapy -- how effective are the therapy strategies?].
    Hanisch E
    Chirurg; 2008 Sep; 79(9):877. PubMed ID: 18682905
    [No Abstract]   [Full Text] [Related]  

  • 48. Immunomodulation in sepsis: state of the art and future perspective.
    Antonopoulou A; Giamarellos-Bourboulis EJ
    Immunotherapy; 2011 Jan; 3(1):117-28. PubMed ID: 21174562
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel therapies for sepsis: a review.
    Deans KJ; Haley M; Natanson C; Eichacker PQ; Minneci PC
    J Trauma; 2005 Apr; 58(4):867-74. PubMed ID: 15824673
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A definite role for treatment with activated protein C in sepsis? Yes.
    Wiel E; Vallet B
    J Thromb Haemost; 2003 Dec; 1(12):2466-8. PubMed ID: 14675078
    [No Abstract]   [Full Text] [Related]  

  • 51. Low-dose heparin for severe sepsis.
    Davidson BL; Geerts WH; Lensing AW
    N Engl J Med; 2002 Sep; 347(13):1036-7. PubMed ID: 12324565
    [No Abstract]   [Full Text] [Related]  

  • 52. Problems of stopping trials early.
    Guyatt GH; Briel M; Glasziou P; Bassler D; Montori VM
    BMJ; 2012 Jun; 344():e3863. PubMed ID: 22705814
    [No Abstract]   [Full Text] [Related]  

  • 53. [Recombinant human activated protein C for sepsis: When should it be indicated?].
    Beer I
    Rev Assoc Med Bras (1992); 2003; 49(3):232-3. PubMed ID: 14666333
    [No Abstract]   [Full Text] [Related]  

  • 54. Age bias in clinical trials in sepsis: how relevant are guidelines to older people?
    Rajapakse S; Rajapakse A
    J Crit Care; 2009 Dec; 24(4):609-13. PubMed ID: 19327329
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A definite role for treatment with activated protein C in sepsis? Standard use is premature.
    Girbes AR; Polderman KH
    J Thromb Haemost; 2003 Dec; 1(12):2469-71. PubMed ID: 14675079
    [No Abstract]   [Full Text] [Related]  

  • 56. Activated protein C in sepsis.
    Taylor FB; Kinasewitz G
    J Thromb Haemost; 2004 May; 2(5):708-17. PubMed ID: 15099275
    [No Abstract]   [Full Text] [Related]  

  • 57. Clinical expert round table discussion (session 5) at the Margaux Conference on Critical Illness: outcomes of clinical trials in sepsis: lessons learned.
    Vincent JL; Angus D; Annane D; Bernard G; Faist E; Giroir B; Reinhart K
    Crit Care Med; 2001 Jul; 29(7 Suppl):S136-7. PubMed ID: 11445749
    [No Abstract]   [Full Text] [Related]  

  • 58. Recombinant human activated protein C in a liver transplant recipient in the immediate postoperative period.
    Rewari V; Milan ZB; Attia M; Davies M
    Anaesth Intensive Care; 2011 Jul; 39(4):771-2. PubMed ID: 21823404
    [No Abstract]   [Full Text] [Related]  

  • 59. Of armoured personnel carriers and magic bullets.
    Leslie GD
    Aust Crit Care; 2002 Feb; 15(1):3. PubMed ID: 11979988
    [No Abstract]   [Full Text] [Related]  

  • 60. What are the challenges of translating positive trial results in severe sepsis into clinical practice? A media roundtable debate, 18 March 2002, Brussels, Belgium.
    Ball J
    Crit Care; 2002 Jun; 6(3):271-4. PubMed ID: 12133192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.